

## IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES

### FIELD OF THE INVENTION

The present invention is directed to improved methods and compositions for synthesis of oligonucleotides and other phosphorus-linked oligomers, without the need for phosphoryl protecting groups. Oligomers synthesized using the methods of the invention are useful for diagnostic reagents, research reagents and in therapeutics.

### BACKGROUND OF THE INVENTION

It is well known proteins are significantly involved in many of the bodily states in multicellular organisms, including most disease states. Such proteins, either acting directly or through their enzymatic or other functions, contribute in major proportion to many diseases and regulatory functions in animals and man. For disease states, classical therapeutics has generally focused upon interactions with such proteins in efforts to moderate their disease-causing or disease-potentiating functions. In newer therapeutic approaches, modulation of the production of such proteins is desired. By interfering with the production of proteins, the maximum therapeutic effect might be obtained with minimal side effects. It is the general object of such therapeutic approaches to interfere with or otherwise modulate gene expression which would lead to undesired protein formation.

One method for inhibiting specific gene expression is with the use of

oligonucleotides, especially oligonucleotides which are complementary to a specific target messenger RNA (mRNA) sequence.

Transcription factors interact with double-stranded DNA during regulation of transcription. Oligonucleotides can serve as competitive inhibitors of transcription factors 5 to modulate the action of transcription factors. Several recent reports describe such interactions (see Bielinska, A., et. al., *Science*, 1990, 250, 997-1000; and Wu, H., et. al., *Gene*, 1990, 89, 203-209).

In addition to functioning as both indirect and direct regulators of proteins, oligonucleotides have also found use in diagnostic tests. Such diagnostic tests can be 10 performed using biological fluids, tissues, intact cells or isolated cellular components. As with gene expression inhibition, diagnostic applications utilize the ability of oligonucleotides to hybridize with a complementary strand of nucleic acid. Hybridization is the sequence specific hydrogen bonding of oligonucleotides, via Watson-Crick and/or Hoogsteen base pairs, to RNA or DNA. The bases of such base pairs are said to be 15 complementary to one another.

Oligonucleotides are also widely used as research reagents. They are useful for understanding the function of many other biological molecules as well as in the preparation of other biological molecules. For example, the use of oligonucleotides as primers in polymerase chain reactions (PCR) has given rise to an expanding commercial 20 industry. PCR has become a mainstay of commercial and research laboratories, and applications of PCR have multiplied. For example, PCR technology is used in the fields of forensics, paleontology, evolutionary studies and genetic counseling. Commercialization has led to the development of kits which assist non-molecular biology-trained personnel in applying PCR. Oligonucleotides, both natural and synthetic, are employed as primers in 25 PCR technology.

Laboratory uses of oligonucleotides are described generally in laboratory manuals such as *Molecular Cloning, A Laboratory Manual*, Second Ed., J. Sambrook, et al., Eds., Cold Spring Harbor Laboratory Press, 1989; and *Current Protocols In Molecular Biology*, F. M. Ausubel, et al., Eds., Current Publications, 1993. Such uses include 30 Synthetic Oligonucleotide Probes, Screening Expression Libraries with Antibodies and Oligonucleotides, DNA Sequencing, In Vitro Amplification of DNA by the Polymerase

Chain Reaction and Site-directed Mutagenesis of Cloned DNA (*see Book 2 of Molecular Cloning, A Laboratory Manual, ibid.*) and DNA-Protein Interactions and The Polymerase Chain Reaction (*see Vol. 2 of Current Protocols In Molecular Biology, ibid.*).

Oligonucleotides can be custom-synthesized for a desired use. Thus a number of chemical modifications have been introduced into oligonucleotides to increase their usefulness in diagnostics, as research reagents and as therapeutic entities. Such modifications include those designed to increase binding to a target strand (i.e. increase their melting temperatures, (Tm)); to assist in identification of the oligonucleotide or an oligonucleotide-target complex; to increase cell penetration; to stabilize against nucleases and other enzymes that degrade or interfere with the structure or activity of the oligonucleotides; to provide a mode of disruption (terminating event) once sequence-specifically bound to a target; and to improve the pharmacokinetic properties of the oligonucleotides.

Thus, it is of increasing value to prepare oligonucleotides and other phosphorus-linked oligomers for use in basic research or for diagnostic or therapeutic applications. Consequently, and in view of the considerable expense and time required for synthesis of specific oligonucleotides, there has been a longstanding effort to develop successful methodologies for the preparation of specific oligonucleotides with increased efficiency and product purity.

Synthesis of oligonucleotides can be accomplished using both solution phase and solid phase methods. Oligonucleotide synthesis via solution phase in turn can be accomplished with several coupling mechanisms. However, solution phase chemistry requires purification after each internucleotide coupling, which is labor intensive and time consuming.

The current method of choice for the preparation of naturally occurring oligonucleotides, as well as modified oligonucleotides such as phosphorothioate and phosphorodithioate oligonucleotides, is via solid-phase synthesis wherein an oligonucleotide is prepared on a polymer support (a solid support) such as controlled pore glass (CPG); oxalyl-controlled pore glass (*see, e.g., Alul, et al., Nucleic Acids Research 1991, 19, 1527*); TENTAGEL Support, (*see, e.g., Wright, et al., Tetrahedron Letters 1993, 34, 3373*); or POROS, a polystyrene resin available from Perceptive Biosystems.

Solid-phase synthesis relies on sequential addition of nucleotides to one end of a growing oligonucleotide chain. Typically, a first nucleoside (having protecting groups on any exocyclic amine functionalities present) is attached to an appropriate glass bead support and activated phosphite compounds (typically nucleotide phosphoramidites, also bearing appropriate protecting groups) are added stepwise to elongate the growing oligonucleotide. The nucleotide phosphoramidites are reacted with the growing oligonucleotide using "fluidized bed" technology to mix the reagents. The known silica supports suitable for anchoring the oligonucleotide are very fragile and thus cannot be exposed to aggressive mixing. Brill, W. K. D., et al. *J. Am. Chem. Soc.*, **1989**, *111*, 2321, disclosed a procedure wherein an aryl mercaptan is substituted for the nucleotide phosphoramidite to prepare phosphorodithioate oligonucleotides on glass supports.

Additional methods for solid-phase synthesis may be found in Caruthers U.S. Patents Nos. 4,415,732; 4,458,066; 4,500,707; 4,668,777; 4,973,679; and 5,132,418; and Koster U.S. Patents Nos. 4,725,677 and Re. 34,069.

The preparation of synthetic oligodeoxynucleotides is currently a well-established procedure that is carried out automatically on solid phase using either phosphoramidite (See (a) Caruthers, M. H. *Acc. Chem. Res.* **1991**, *24*, 278–284; (b) Beaucage, S. L.; Iyer, R. P. *Tetrahedron* **1992**, *48*, 2223–2311) or H-phosphonate chemistry (See (a) Hall, R. H.; Todd, A.; Webb, R. F. *J. Chem. Soc.* **1957**, 3291–3296; (b) Garegg, P. J.; Regberg, T.; Stawinski, J.; Strömberg, R. *Chem. Scripta* **1985**, *25*, 280–282; (c) Froehler, B. C.; Matteucci, M. D. *Tetrahedron Lett.* **1986**, *27*, 469–472). In both approaches, the synthesis is implemented by stepwise coupling of monomeric nucleoside building blocks to the 5'-terminus of the oligonucleotide chain to be elongated. In the phosphoramidite elongation cycle, the newly formed phosphite triester moiety is subsequently oxidized to give the phosphate triester or sulfurized to the thionophosphate triester. These moieties remain protected until the completion of the synthesis. The phosphate protecting group (or "phosphoryl protecting group"), which is most often the 2-cyanoethyl group (See (a) Sinha, N. D.; Biernat, J.; Köster, H. *Tetrahedron Lett.* **1983**, *24*, 5843–5846; and (b) Sinha, N. D.; Biernat, J.; McManus, J.; Köster, H. *Nucleic Acids Res.* **1984**, *12*, 4539–4557), is then removed under basic conditions. Thus, the

2-cyanoethyl or other phosphate protecting groups are not removed until the final deprotection of an oligonucleotide.

However, it has been reported that *o*-methylbenzyl protection can be removed by treatment with a solution of iodine during the normal oxidation protocol (See

- 5 Caruthers, M. H. Kierzek, R.; Tang, J. Y. In *Biophosphates and their Analogues – Synthesis, Structure, Metabolism and Activity*; Bruzik, K. S.; and Stec, W. J. Eds.; Esevier: Amsterdam, 1987; pp. 3–21). Thymidine *o*-methylbenzyl phosphoramidite was shown to couple to the 5'-hydroxy group of phosphate-unprotected, solid support-bound oligodeoxyribonucleotides to afford eicosathymidylate with an average stepwise yield of  
10 96%, which is not optimal for synthesis of phosphodiester and phosphorothioate oligonucleotides.

In addition, it is often desirable to prepare oligonucleotides having a plurality of regions that differ with respect to internucleoside linkage, for example oligonucleotides with mixed backbones that require the successive use of *H*-phosphonate and  
15 phosphoramidite approaches. There is a need for synthetic methodologies for the preparation of such compounds, that provide for the coupling of phosphoramidite synthons to growing oligonucleotide or oligonucleotide analog chains that possess unprotected phosphoryl protecting groups, with high yield. There also is a need for efficient methodologies for the synthesis of oligonucleotides and their analogs that provide for the  
20 use of very labile phosphate protecting groups that can be removed under standard automated synthesis conditions. The present invention is directed to these, as well as other, important ends.

## SUMMARY OF THE INVENTION

The present invention provides improved methods for the preparation of  
25 oligonucleotides and other phosphorus-linked oligomers. In some preferred embodiments, the present invention provides methods for the preparation of oligonucleotides and phosphorus-linked oligomers wherein monomeric or higher order subunits are added to growing oligomer chains that possess one or more phosphoryl internucleoside linkages that do not bear phosphoryl protecting groups.


Thus, in accordance with some preferred embodiments of the invention, methods are provided comprising reacting a nucleoside phosphoramidite with a support bound oligomer in the presence of a neutralizing agent, said support bound oligomer having at least one unprotected internucleoside linkage selected from the group consisting of 5 phosphate linkages, phosphorothioate linkages, and phosphorodithioate linkages; wherein said neutralizing agent is:

an aliphatic amine, an aliphatic heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, a guanidine, or a salt of formula  $D^+ E^-$  wherein:

10            $D^+$  is a quaternary tetraalkylammonium cation, or a protonated form of an aliphatic amine, an aliphatic heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, or a guanidine; and

15            $E^-$  is a tetrazolate anion, 4,5-dicyanoimidazolate anion, a substituted or unsubstituted alkylsulfonate anion, a substituted or unsubstituted arylsulfonate anion, tetrafluoroborate anion, hexafluorophosphate anion, or a trihaloacetate anion.

In further preferred embodiments, the present invention provides methods of 20 forming an internucleoside linkage comprising reacting a phosphoramidite of formula:



wherein:

L<sub>1</sub> is an internucleoside linkage;

n<sub>1</sub> is 0 to about 100;

5 R<sub>1</sub> is a hydroxyl protecting group;

R<sub>2</sub> is a 2'-substituent group;


R<sub>4</sub> and R<sub>5</sub> are each independently alkyl having from 1 to about 10 carbon atoms, or R<sub>4</sub> and R<sub>5</sub> taken together with the nitrogen atom to which they are attached form a heterocycle;

10 B is a nucleobase;

Q is O or S;

Pg is a phosphoryl protecting group;

with a compound of formula:




wherein

$R_3$  is a linker connected to a solid support;

n is from 1 to 100; and

5 L is an internucleoside linkage of formula:



wherein:

Z is O or S;

X is O or S; and

Y is a phosphoryl protecting group or a negative charge;

provided that at least one Y is a negative charge;

wherein said reaction is performed in the presence of a neutralizing agent;

wherein said neutralizing agent is:

an aliphatic amine, an aliphatic heterocyclic amine, an

15 aromatic amine, an aromatic heterocyclic amine, a guanidine, or a salt

of formula  $D^+ E^-$  wherein:

$D^+$  is a quaternary tetraalkylammonium cation, or a protonated form of an aliphatic amine, an aliphatic heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, or a guanidine; and

5            $E^-$  is a tetrazolide anion, 4,5-dicyanoimidazolide anion, a substituted or unsubstituted alkylsulfonate anion, a substituted or unsubstituted arylsulfonate anion, tetrafluoroborate anion, hexafluorophosphate anion, or a trihaloacetate anion.

10

In accordance with further preferred embodiments of the invention, methods are provided comprising the steps of:

- (a) providing a solid support having a 5'-O-protected phosphorus-linked oligomer bound thereto, said phosphorus-linked oligomer having at least one phosphoryl 15 internucleoside linkage that does not bear a phosphoryl protecting group;
- (b) deprotecting the 5'-hydroxyl of the phosphorus-linked oligomer with a deprotecting reagent;
- (c) washing the deprotected phosphorus-linked oligomer on the solid support with a solution containing a neutralizing agent;
- 20 (d) reacting the deprotected 5'-hydroxyl with an 5'-protected nucleoside phosphoramidite to produce a phosphate triester linkage therebetween; and
- (e) oxidizing or sulfurizing the covalent linkage to form a phosphodiester, phosphorothioate, or phosphorodithioate linkage; and  
optionally repeating steps b through e at least once for subsequent couplings 25 of additional nucleoside phosphoramidites;

wherein said neutralizing agent is:

an aliphatic amine, an aliphatic heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, a guanidine, or a salt of formula  $D^+ E^-$  wherein:

30

$D^+$  is a quaternary tetraalkylammonium cation, or a protonated form of an aliphatic amine, an aliphatic

heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, or a guanidine; and

E<sup>-</sup> is a tetrazolide anion, 4,5-dicyanoimidazolide anion, a substituted or unsubstituted alkylsulfonate anion, a substituted or unsubstituted arylsulfonate anion, tetrafluoroborate anion, hexafluorophosphate anion, or a trihaloacetate anion.

In accordance with still further preferred embodiments of the invention, methods are provided comprising the steps of:

- 10 (a) providing a solid support having a 5'-O-protected phosphorus-linked oligomer bound thereto, said phosphorus-linked oligomer having at least one phosphoryl internucleoside linkage that does not bear a phosphoryl protecting group;
- (b) deprotecting the 5'-hydroxyl of the 5'-O-protected phosphorus-linked oligomer with a deprotecting reagent to form a support bound 5'-deprotected phosphorus-linked oligomer;
- 15 (c) optionally washing the 5'-deprotected phosphorus-linked oligomer on the solid support;
- (d) contacting the support bound 5'-deprotected phosphorus-linked oligomer with a solution comprising a 5'-protected nucleoside phosphoramidite to produce a phosphite triester linkage therebetween, wherein said solution further comprises a neutralizing agent; and
- 20 (e) oxidizing or sulfurizing the phosphite triester linkage to form a phosphodiester, phosphorothioate, or phosphorodithioate linkage; and  
optionally repeating steps b through e at least once for subsequent couplings of additional nucleoside phosphoramidites;
- 25 wherein said neutralizing agent is:

an aliphatic amine, an aliphatic heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, a guanidine, or a salt of formula D<sup>+</sup>E<sup>-</sup> wherein:

- 30 D<sup>+</sup> is a quaternary tetraalkylammonium cation, or a protonated form of an aliphatic amine, an aliphatic

heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, or a guanidine; and

E<sup>-</sup> is a tetrazolide anion, 4,5-dicyanoimidazolide anion,

a substituted or unsubstituted alkylsulfonate anion, a

5 substituted or unsubstituted arylsulfonate anion,

tetrafluoroborate anion, hexafluorophosphate anion, or a

trihaloacetate anion.

In some preferred embodiments of the forgoing methods, the neutralizing agent is a salt of formula D<sup>+</sup>E<sup>-</sup>. In some preferred embodiments E<sup>-</sup> is a tetrazolide anion, 10 preferably 1H-tetrazolide anion, 5-methylthio-1H-tetrazolide anion, 5-ethylthio-1H-tetrazolide anion or 1-phenyl-5-thiol-1H-tetrazolide anion, with 1H-tetrazolide anion being most preferred.

In some preferred embodiments, D<sup>+</sup> is a protonated form of any of an alkyl, alkenyl or alkynyl amine having from one to about 20 carbons, an aliphatic heterocyclic amine, an aromatic heterocyclic amine, or a guanidine. 15

In some preferred embodiments, the protonated form of an alkyl amine is a protonated form of trimethyl amine, triethyl amine, triisopropyl amine, tributyl amine, triamyl amine, isopropyldimethyl amine, t-butyldimethyl amine, diisopropylethyl amine, or N,N,N',N'-tetramethyl-1,2-diaminoethane.

20 In further preferred embodiments, D<sup>+</sup> is a protonated form of an aliphatic heterocyclic amine, which is preferably a protonated form of any of DBU, -methylmorpholine, N-methylpyrrolidine, N-methylpiperidine, N,N'-dimethylpiperazine, N-ethylpyrrolidine, N-ethylpiperidine, N,N'-diethylpiperazine, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, or 1,5,7-triazabicyclo[4.4.0]dec-5ene.

25 In further preferred embodiments, D<sup>+</sup> is a protonated form of an aromatic heterocyclic amine, which is preferably a protonated form of a mono-, di- or trialkyl pyridine that is optionally substituted with an amino group, with a protonated form of any of 2,4,6-collidine, 2,6-lutidine, pyridine, 2-methylpyridine, 2,6-diethylpyridine, 2,6-di(t-butyl)pyridine, 4-methyl-2,6-di(t-butyl)pyridine, or 2,4,6-tri(t-butyl)pyridine being preferred, and with a protonated form of an alkylamino substituted pyridine being more preferred, and with a protonated form of 4-dimethylaminopyridine being even more

30

preferred.

In further preferred embodiments  $D^+$  is a protonated form of guanidine, preferably tetraalkyl guanidine, with a protonated form of N,N,N'N'-tetramethylguanidine being more preferred.

5 In still further preferred embodiments,  $D^+$  is a quaternary tetraalkylammonium cation which is preferably a tetramethylammonium, tetraethylammonium, tetrapropylammonium, tetrabutylammonium, trimethyloctylammonium, or triethylbenzylammonium cation.

In further preferred embodiments,  $E^-$  is 4,5-dicyanoimidazolide anion.

10 In still further preferred embodiments,  $E^-$  is a substituted or unsubstituted alkylsulfonate anion, with methylsulfonate anion or trifluoromethylsulfonate anion being more preferred.

15 In some preferred embodiments,  $E^-$  is a substituted or unsubstituted arylsulfonate anion, with a methylphenylsulfonate anion or a trihalomethylphenylsulfonate anion being more preferred. Preferably, the trihalomethylphenylsulfonate anion is trifluoromethylphenylsulfonate anion.

In further preferred embodiments  $E^-$  is tetrafluoroborate anion, hexafluorophosphate anion, or a trihaloacetate anion, which is preferably trifluoroacetate anion.

20 In certain preferred embodiments,  $E^-$  is a tetrazolide anion or substituted or unsubstituted alkylsulfonate anion, and  $D^+$  is a tetramethylammonium, tetraethylammonium, tetrapropylammonium, tetrabutylammonium, trimethyloctylammonium, or triethylbenzylammonium cation. In further preferred embodiments,  $E^-$  is trifluoromethanesulfonate anion and  $D^+$  is a protonated form of N-methylimidazole, N-ethylimidazole, or 1, 2, 4-triazole.

25 In some more preferred embodiments,  $D^+$  is a protonated form of trimethyl amine, triethyl amine, triisopropyl amine, tributyl amine, triamyl amine, isopropyldimethyl amine, t-butyldimethyl amine, diisopropylethyl amine, N,N,N',N'-tetramethyl-1,2-diaminoethane, DBU, N-methylmorpholine, N-methylpyrrolidine, N-methylpiperidine, N,N'-dimethylpiperazine, N-ethylpyrrolidine, N-ethylpiperidine, N,N'-diethylpiperazine, 30 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, or 1,5,7-

triazabicyclo[4.4.0]dec-5ene, 2,4,6-collidine, 2,6-lutidine, pyridine, 2-methylpyridine, 2,6-diethylpyridine, 2,6-di(t-butyl)pyridine, 4-methyl-2,6-di(t-butyl)pyridine, or 2,4,6-tri(t-butyl)pyridine, 4-dimethylaminopyridine, or N,N,N'N'-tetramethylguanidine, or tetramethylammonium, tetraethylammonium, tetrapropylammonium, tetrabutylammonium,  
5 trimethyloctylammonium, or triethylbenzylammonium cation; and

E<sup>-</sup> is 1H-tetrazolate anion, 4,5-dicyanoimidazolate anion, methylsulfonate anion, trifluoromethylsulfonate anion, methylphenylsulfonate anion, trifluoromethylphenylsulfonate anion, tetrafluoroborate anion, hexafluorophosphate anion, or trifluoroacetate anion.

In some further preferred embodiments of the methods of the invention, Q is O; Z is O; Pg is β-cyanoethyl, methyl, (N-methyl-N-benzoylamino)ethyl, (N-ethyl-N-benzoylamino)ethyl, 2-[N-methyl-N-(4-methoxybenzoyl)amino]ethyl, 2-(N-isopropyl-N-benzoylamino)ethyl, 2-[N-ethyl-N-(4-methoxybenzoyl)amino]ethyl, 2-[N-isopropyl-N-(4-methoxybenzoyl)amino]ethyl, 2-[N-methyl-N-(4-dimethylaminobenzoyl)amino]ethyl, 2-[N-ethyl-N-(4-dimethylaminobenzoyl)amino]ethyl, 2-[N-isopropyl-N-(4-dimethylaminobenzoyl)amino]ethyl, 2-(thionobenzoylamino)ethyl, 3-(thionobenzoyl-amino)propyl, 2-(N-phenylthiocarbamoylamino)ethyl, 2-[(1-naphthyl)carbamoyloxy]ethyl, diphenylsilylethyl, δ-cyanobutenyl, cyano p-xylyl, methyl-N-trifluoroacetyl ethyl or acetoxy phenoxy ethyl; and Y is β-cyanoethyl, allyl, methyl, (N-methyl-N-benzoylamino)ethyl, (N-ethyl-N-benzoylamino)ethyl, 2-[N-methyl-N-(4-methoxybenzoyl)-amino]ethyl, 2-(N-isopropyl-N-benzoylamino)ethyl, 2-[N-ethyl-N-(4-methoxybenzoyl)-amino]ethyl, 2-[N-isopropyl-N-(4-methoxybenzoyl)amino]ethyl, 2-[N-methyl-N-(4-dimethylaminobenzoyl)amino]ethyl, 2-[N-ethyl-N-(4-dimethylaminobenzoyl)amino]ethyl, 2-(thionobenzoylamino)ethyl, 3-(thionobenzoyl-amino)propyl, 2-(N-phenylthiocarbamoylamino)ethyl, 2-[(1-naphthyl)carbamoyloxy]ethyl, diphenylsilylethyl, δ-cyanobutenyl, cyano p-xylyl, methyl-N-trifluoroacetyl ethyl, acetoxy phenoxy ethyl, or a negative charge.

In further more preferred embodiments, the neutralizing agent is a salt of formula D<sup>+</sup>E<sup>-</sup> where E<sup>-</sup> is a tetrazolate anion which is preferably 1H-tetrazolate anion; D<sup>+</sup> is a protonated form of dimethylaminopyridine; Pg is β-cyanoethyl, diphenylsilylethyl, δ-cyanobutenyl, cyano p-xylyl, methyl-N-trifluoroacetyl ethyl or acetoxy phenoxy ethyl; and

Y is  $\beta$ -cyanoethyl, allyl, diphenylsilyl ethyl,  $\delta$ -cyanobut enyl, cyano *p*-xylyl, methyl-N-trifluoroacetyl ethyl, acetoxy phenoxy ethyl or a negative charge.

In accordance with further preferred embodiments, the present invention provides compositions comprising a 5'-protected nucleoside phosphoramidite and a salt of formula D<sup>+</sup>E<sup>-</sup> wherein:

D<sup>+</sup> is a quaternary tetraalkylammonium cation, or a protonated form of an aliphatic amine, an aliphatic heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, or a guanidine; and

E<sup>-</sup> is a tetrazolide anion, 4,5-dicyanoimidazolide anion, a substituted or unsubstituted alkylsulfonate anion, a substituted or unsubstituted arylsulfonate anion, tetrafluoroborate anion, hexafluorophosphate anion, or a trihaloacetate anion.

In some preferred embodiments of the compositions of the invention, E<sup>-</sup> is a tetrazolide anion which is preferably 1H-tetrazolide anion; and D<sup>+</sup> is a protonated form of a mono-, di- or trialkyl pyridine that is optionally substituted with an amino group, which is preferably a protonated form of dimethylaminopyridine.

In accordance with further preferred embodiments, the present invention provides compositions as described above, and further comprising a solid support having an oligonucleotide or oligonucleotide analog bound thereto, said oligonucleotide or oligonucleotide analog having at least one phosphoryl internucleoside linkage that does not bear a phosphoryl protecting group.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the total yields of the 5'-segments of 16a (squares) and 18a (circles) as a function of pK<sub>BH+</sub> (MeCN) values of protonated nitrogen bases. (a) Standard cycle (shown as a horizontal grid); (b) Py; (c) Lut; (d) Col; (e) NMM; (f) DIPEA; (g) TEA.

Figure 2 shows the total yields of the 5'-segments of 16a (squares) and 18a (circles) as a function of pK<sub>BH+</sub> (MeCN) values of protonated nitrogen bases. (a) Standard cycle (shown as a horizontal grid); (b) Py; (c) Lut; (d) Col; (e) NMM-Tet; (f) DMAP-Tet; (g) DIPEA-Tet; (h) TEA-Tet; (I) TBD-Tet; (k) DBU-Tet.

Figure 3 shows the total yields of the 5'-segments of **16b** (■) and **18b** (●) as a function of  $pK_{BH^+}$  (MeCN) values of protonated nitrogen bases. (a) Standard cycle (shown as a horizontal grid); (b) Py; (c) Lut; (d) Col; (e) NMM-Tet; (f) DMAP-Tet; (g) DIPEA-Tet; (h) TEA-Tet; (I) TBD-Tet; (k) DBU-Tet.

5 Figure 4 shows the  $^{31}P$  NMR Spectrum of **3a** in gel phase ( $CD_3CN$  as a liquid phase).

Figure 5 shows the  $^{31}P$  NMR Spectrum of **4a** in Gel Phase (1M Piperidine in  $CD_3CN$  as a liquid phase).

10 Figure 6 shows the  $^{31}P$  NMR Spectrum of **6a** in Gel Phase (5% Pyridine in  $CD_3CN$  as a liquid phase).

Figure 7 shows the  $^{31}P$  NMR Spectrum of **7a** in Gel Phase (5% Pyridine in  $CD_3CN$  as a liquid phase).

Figure 8 shows the  $^{31}P$  NMR Spectrum of **8a** in Gel Phase (5% Pyridine in  $CD_3CN$  as a liquid phase).

15 Figure 9 shows the Reverse Phase HPLC Profile for Oligonucleotide **9a** Obtained Using the Standard Cycle (Crude Deprotection Mixture).

Figure 10 shows the  $^{31}P$  NMR Spectrum of **4b** in Gel Phase (1M Piperidine in  $CD_3CN$  as a liquid phase).

20 Figure 11 shows the  $^{31}P$  NMR Spectrum of **8b** in Gel Phase (5% Pyridine in  $CD_3CN$  as a liquid phase).

Figure 12 shows the Reverse Phase HPLC Profile for Oligonucleotide **9b** Obtained Using the Standard Cycle (Crude Deprotection Mixture).

Figure 13 shows the Reverse Phase HPLC Profile for Oligonucleotide **16a** Obtained Using the Standard Cycle (Crude Deprotection Mixture).

25 Figure 14 shows the Reverse Phase HPLC Profile for Oligonucleotide **18a** Obtained Using the Standard Cycle (Crude Deprotection Mixture).

Figure 15 shows the Reverse Phase HPLC Profile for Oligonucleotide **16b** Obtained Using the Standard Cycle (Crude Deprotection Mixture).

30 Figure 16 shows the Reverse Phase HPLC Profile for Oligonucleotide **18b** Obtained Using the Standard Cycle (Crude Deprotection Mixture).

Figure 17 shows the Reverse Phase HPLC Profile for Oligonucleotide 16a Obtained Using the Optimized Cycle (Crude Deprotection Mixture).

Figure 18 shows the Reverse Phase HPLC Profile for Oligonucleotide 18a Obtained Using the Optimized Cycle (Crude Deprotection Mixture).

5 Figure 19 shows the Reverse Phase HPLC Profile for Oligonucleotide 16b Obtained Using the Optimized Cycle (Crude Deprotection Mixture).

Figure 20 shows the Reverse Phase HPLC Profile for Oligonucleotide 18b Obtained Using the Optimized Cycle (Crude Deprotection Mixture).

10 Figure 21 shows the Reverse Phase HPLC Profile for Oligonucleotide 32a Obtained Using the Optimized Cycle (Crude Deprotection Mixture).

Figure 22 shows the Reverse Phase HPLC Profile for Oligonucleotide 32b Obtained Using the Optimized Cycle (Crude Deprotection Mixture).

## DETAILED DESCRIPTION

In some preferred embodiments, the present invention provides methods and 15 compositions for the preparation of phosphorus-linked oligomers wherein monomeric or higher order subunits are added to growing oligomer chains that possess one or more phosphoryl internucleoside linkages (for example, phosphodiester, phosphorothioate, phosphorodithioate or H-phosphonate linkages) that do not bear phosphoryl protecting groups. The methods of the invention provide stepwise yields of oligomer that are higher 20 than those obtained in the absence of the neutralizing agents of the invention, particularly when the support bound oligomer to be extended has multiple unprotected phosphoryl internucleoside linkages.

In accordance with some preferred embodiments of the invention, the efficiency of the coupling reaction between phosphoramidite and support-bound oligomer 25 containing at least one unprotected phosphoryl internucleoside linkage is raised to, or exceeds, the commonly accepted levels for synthesis of oligomers that include, for example, phosphodiester linkages, phosphorothioate linkages, or mixtures thereof.

In some further preferred embodiments of the methods of the invention, an oligonucleotide synthon having a 3'-phosphoramidite group, and at least one unprotected 30 phosphoryl internucleoside linkage, is coupled to a support-bound monomeric or higher

order oligomer having an unprotected 3'-hydroxyl, and, optionally, one or more unprotected phosphoryl internucleoside linkages, in the presence of a neutralizing agent as described herein. Thus, in accordance with the methods of the present invention, the unprotected phosphoryl internucleoside linkage or linkages can reside in the

5 phosphoramidite synthon, the support bound oligomer, or both.

In the context of the present invention, the term "phosphorus-linked oligomer" refers to a plurality (i.e., greater than two) of joined nucleobase-bearing monomeric subunits that are connected by linking groups, wherein at least one of the linking groups contains a phosphorus atom. Examples of phosphorus-linked oligomers

10 include those that contain one or more phosphodiester, phosphotriester, phosphorothioate, phosphorodithioate, and H-phosphonate linkages, although phosphorus-linked oligomers may also contain one or more non-phosphorus containing linkages between monomeric subunits. As used herein, the term "internucleoside linkage" is intended to mean a linkage between hydroxyl groups of two nucleosidic sugars (e.g., ribose, substituted ribose, or

15 analogs thereof).

In accordance with some preferred embodiments of the invention, a support bound dimer or oligomer having at least one unprotected phosphorus-containing internucleoside linkage (i.e., at least one unprotected phosphoryl linkage) is reacted with a nucleoside phosphoramidite in the presence of a neutralizing agent to produce an

20 internucleoside linkage in high yield. In accordance with some preferred methods of the invention, such support bound oligomer can have one or more types of phosphorus containing linkages, each of which may be protected (i.e., bear a phosphoryl protecting group) or be unprotected (i.e., lack such a phosphoryl protecting group). Examples of such types of phosphorus containing internucleoside linkages include phosphate linkages,

25 phosphorothioate linkages, phosphorodithioate linkages, and H-phosphonate linkages.

In some preferred embodiments of the methods of the invention, the reaction between the nucleoside phosphoramidite and the support bound oligomer is performed in the presence of a neutralizing agent that is an aliphatic amine, an aliphatic heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, a guanidine, or a salt of formula

30  $D^+ E^-$  wherein:

$D^+$  is a quaternary tetraalkylammonium cation, or a protonated form

of an aliphatic amine, an aliphatic heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, or a guanidine; and

5           E<sup>-</sup> is a tetrazolate anion, 4,5-dicyanoimidazolide anion, a substituted or unsubstituted alkylsulfonate anion, a substituted or unsubstituted arylsulfonate anion, tetrafluoroborate anion, hexafluorophosphate anion, or a trihaloacetate anion.

The neutralizing agent can be applied in a washing step, prior to coupling of a phosphoramidite, or can be included in the solution applied in the coupling step, along with the nucleoside phosphoramidite to be coupled. Thus, the invention provides for  
10 methods for oligonucleotide synthesis wherein a washing step is employed wherein the washing solution contains a neutralizing agent of the invention. Also provided by the present invention are methods for oligonucleotide synthesis wherein a neutralizing agent as described herein is included within the solution containing nucleoside or higher order phosphoramidite to be coupled to a growing oligomer chain.

15           As used herein, the term "a tetrazole" is intended to include 1*H*-tetrazole and substituted 1*H*-tetrazoles. Substituted 1*H*-tetrazoles include lower alkyl substituted (i.e., C<sub>1</sub>-C<sub>6</sub>)-1*H*-tetrazoles, lower alkylthio substituted 1*H*-tetrazoles for example 5-methylthio-1*H*-tetrazole and 5-ethylthio-1*H*-tetrazole, and tetrazoles having both thiol and lower alkyl or aryl substituents, for example 1-phenyl-5-thiol-1*H*-tetrazole. Also included in the  
20 definition of "a tetrazole" are nitrotetrazoles and N,N-diisopropylaminohydrotetrazolide. As used herein the term "a tetrazolate anion" is intended to mean the corresponding anionic form of a tetrazole, after removal of a proton.

As used herein, the term "tetrazolide" is intended to mean the salt that results from a tetrazole, preferably a 1*H*-tetrazole, and a base.

25           In some preferred embodiments, the support bound oligomer chain that is desired to be elongated can have one, two, or a plurality of unprotected phosphorus-containing linkages. Thus, in some preferred embodiments, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about  
30 85%, about 90%, about 95% or about 100% of the phosphorus containing linkages of the support bound oligomer can be unprotected.

In addition to containing at least one unprotected phosphorus-containing internucleoside linkage, the support bound oligomer can contain one or more monomeric units that are linked by protected phosphorus-containing internucleoside linkages. In addition, or alternatively, in some preferred embodiments the support bound oligomer can

5 contain one or more monomeric units that are linked by non-phosphorus containing internucleoside linkages. Examples of such non-phosphorus internucleoside linkages are the methylene-methylimino linkage (See for example Vasseur, J. J., Debart, F., Sanghvi, Y. S., and Cook, P. D.; 1992, *J. Am. Chem. Soc.* **114**, 4006-7), and the morpholino linkage (See Summerton, J. (1999) *Biochim. Biophys. Acta* **1489**, 141-158). In

10 some preferred embodiments, the support bound oligomer contains two or more regions which have different internucleoside linkages. Thus, in some preferred embodiments, the methods of the invention are employed to prepare such "chimeric" oligomers by coupling protected phosphoramidite monomers or higher order phosphoramidite synthons to an oligomer chain having one or more regions of unprotected phosphate, phosphorothioate,

15 phosphorodithioate or H-phosphonate internucleoside linkages.

In other preferred embodiments, the support bound oligomer can contain one regions that do not possess sugar backbones. One example of such a non-sugar backbone is the peptide nucleic acid (PNA). See Nielsen, P. E., Egholm, M., Berg, R. H., and Buchardt, O. 1991, *Science* **254**, 1497-500; Egholm, M., Buchardt, O., Nielsen, P. E., and Berg, R. H. 1992 *J. Am. Chem. Soc.* **114**, 1895-7; and Corey, D. R. 1997 in *Trends Biotechnol.* pp 224-229. Thus, in further preferred embodiments, the methods of the invention are employed to prepare chimeric oligomers by coupling protected phosphoramidite monomers on to an oligomer chain having at least one unprotected phosphoryl linkage and one or more regions of non-sugar backbone.

25 Also provided in accordance with preferred embodiments of the invention are compositions comprising a 5'-protected nucleoside phosphoramidite or higher order phosphoramidite synthon and a salt of formula  $D^+ E^-$  wherein  $D^+$  is a quaternary tetraalkylammonium cation, or a protonated form of an aliphatic amine, an aliphatic heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, or a guanidine;

30 and  $E^-$  is a tetrazolide anion, 4,5-dicyanoimidazolide anion, a substituted or unsubstituted alkylsulfonate anion, a substituted or unsubstituted arylsulfonate anion, tetrafluoroborate

anion, hexafluorophosphate anion, or a trihaloacetate anion. In some preferred embodiments, of the compositions of the invention, E<sup>-</sup> is a tetrazolide anion; and D<sup>+</sup> is a protonated form of a mono-, di- or trialkyl pyridine that is optionally substituted with an amino group. In some particularly preferred embodiments, E<sup>-</sup> is 1H-tetrazolide anion; and

- 5 D<sup>+</sup> is a protonated form of dimethylaminopyridine.

Further preferred embodiments of the compositions of the invention comprise a neutralizing agent as described herein, and a solid support having phosphorus-linked oligomer bound thereto, said phosphorus-linked oligomer having at least one phosphoryl internucleoside linkage that does not bear a phosphoryl protecting group.

10 The compositions of the invention are useful in the preparation of phosphorus-linked oligomers as described herein. The compositions of the invention can be used in research reagents and kits. For synthetic applications, kits containing the compositions of the invention can be conveniently used in standard oligonucleotide synthetic regimes, as described herein.

15 The methods of the invention provide stepwise yields of oligomer that are higher than those obtained in the absence of the neutralizing agents of the invention, particularly when the support bound oligomer to be extended has multiple unprotected phosphoryl internucleoside linkages. In some preferred embodiments, the methods of the invention stepwise yields of 96.5%, 97% 97.2%, 97.4%, 97.6%, 97.8%, 98%, 98.2%,  
20 98.4%, 98.6%, 98.8%, 99%, 99.2%, 99.4%, 99.6% 99.8% or about 100%.

As used herein, the term "aliphatic amine" is intended to mean an aliphatic compound containing at least one amino nitrogen. The term "aliphatic" is intended to mean non-aromatic, although "aliphatic" compounds may have one or more double or triple bonds. Examples of aliphatic amines include alkyl, alkenyl and alkenyl amines, for  
25 example trimethyl amine, triethyl amine, triisopropyl amine, and tributyl amine. In more preferred embodiments, the aliphatic amine is a tertiary amine.

The term "aliphatic heterocyclic amine" is intended to denote an aliphatic amine that contains at least one ring that contains at least one heteroatom. The ring heteroatom can be the amino nitrogen, or another hetero (i.e., noncarbon) atom selected  
30 from O, N and S. Examples of aliphatic heterocyclic amines include 1,8 diazabicyclo[5.4.0] undec-7-ene (DBU), morpholine and alkyl-substituted morpholines

including N-methylmorpholine (NMM), piperazines, including mono-N-alkyl, di-N-alkyl, mono-N-alk and di-N-aryl piperazines, N-alkyl and N-aryl pyrrolidines, and piperidines, including N-alkyl and N-aryl piperidines.

- As used herein, the term "aromatic amine" is intended to mean an aromatic compound that contains at least one amino nitrogen. The term "aromatic heterocyclic amine" is intended to mean an aromatic amine that contains at least one ring that contains at least one heteroatom. The ring heteroatom can be the amino nitrogen, or another hetero (i.e., noncarbon) atom selected from O, N and S. Examples of aromatic heterocyclic amines include pyridine and substituted pyridines including mono-, di- and trialkyl pyridines, alkylamino pyridines, for example dimethylaminopyridine (DMAP), pyrroles including alkyl substituted pyrroles, pyrimidines including alkyl substituted pyrimidines, and imidazoles including alkyl substituted imidazoles.

- As used herein, "alkyl" refers to a hydrocarbon containing from 1 to about 20 carbon atoms. Alkyl groups may straight, branched, cyclic, or combinations thereof. Alkyl groups thus include, by way of illustration only, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, and the like. Also included within the definition of "alkyl" are fused and/or polycyclic aliphatic cyclic ring systems such as, for example, adamantine. As used herein the term "alkenyl" denotes an alkyl group having at least one carbon-carbon double bond. As used herein the term "alkynyl" denotes an alkyl group having at least one carbon-carbon triple bond.

As used herein, the term "heterocycle" is intended to denote a cyclic aliphatic or aromatic compound that contains from one to three ring hetero atoms selected from O, N and S. Examples of heterocycles include morpholine, pyran and pyridine.

- In some preferred embodiments, the aforementioned aliphatic amines, aliphatic heterocyclic amines, aromatic amines, aromatic heterocyclic amines, guanidines (and protonated forms of the foregoing), tetrazolide anions and quaternary tetraalkylammonium cations can be "substituted"; that is, they can bear one or more further substituent groups. In some preferred embodiments these substituent groups can include halogens, CN, NO<sub>2</sub>, lower (i.e., C<sub>1</sub>-C<sub>6</sub>) alkyl groups, alkoxy carbonyl groups, alkoxy groups, and hydroxy groups.


As used therein the term halogen includes fluorine, chlorine, bromine and

iodine.

As used herein the term "aryl" means a group having 5 to about 20 carbon atoms and which contains at least one aromatic ring, such as phenyl, biphenyl and naphthyl. Preferred aryl groups include unsubstituted or substituted phenyl and naphthyl groups, where "substituted" has the meaning described above.

The term "a guanidine" is intended to mean guanidine, and simple mono-, di-, tri- and tetra-N-alkyl substituted guanidines, including N,N,N'N'-tetramethylguanidine.

In accordance with some preferred embodiments of the invention, methods of forming an internucleoside linkage are provided comprising reacting a phosphoramidite of formula:



wherein:

- 15             $L_1$  is an internucleoside linkage;
- $n_1$  is 0 to about 100;
- $R_1$  is a hydroxyl protecting group;
- $R_2$  is a 2'-substituent group;
- $R_4$  and  $R_5$  are each independently alkyl having from 1 to about 10 carbon atoms, or  $R_4$  and  $R_5$  taken together with the nitrogen atom to which they are attached form


a heterocycle;

B is a nucleobase;

Q is O or S;

Pg is a phosphoryl protecting group;

5 with a compound of formula:




wherein

R<sub>3</sub> is a linker connected to a solid support;

n is from 1 to 100; and

10 L is an internucleoside linkage of formula:



wherein:

Z is O or S;

X is O or S; and

Y is a phosphoryl protecting group or a negative charge;

provided that at least one Y is a negative charge;

wherein said reaction is performed in the presence of a neutralizing agent;

5 wherein said neutralizing agent is:

an aliphatic amine, an aliphatic heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, a guanidine, or a salt of formula  $D^+ E^-$  wherein:

$D^+$  is a quaternary tetraalkylammonium cation, or a

10 protonated form of an aliphatic amine, an aliphatic heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, or a guanidine; and

$E^-$  is a tetrazolide anion, 4,5-dicyanoimidazolide anion,

a substituted or unsubstituted alkylsulfonate anion, a substituted or unsubstituted arylsulfonate anion, tetrafluoroborate anion, hexafluorophosphate anion, or a trihaloacetate anion.

As can be seen, the methods of the present invention provide for the use of both mononucleoside phosphoramidite synthons, and higher order (i.e., di-, tri-, tetra- or longer) nucleoside phosphoramidite synthons. Such higher order synthons can have phosphate-containing internucleoside linkages which may be protected or unprotected, and also can have non-phosphate-containing internucleoside linkages. In addition, or alternatively, such synthons can possess regions of non-sugar containing backbone, for example PNA, and/or regions that differ with respect to sugar substituent, for example regions that differ with respect to 2'-substituent. In some preferred embodiments, the methods of the invention are used to couple an oligonucleotide or analog thereof to a solid-support bound di- or higher order oligomeric species, wherein at least one internucleoside linkage in either the phosphoramidite or the support bound species is an unprotected phosphoryl linkage.

30 The methods of the invention are amenable to the preparation of oligonucleotides and analogs thereof having a wide variety of modifications, including

base modifications, backbone modifications, phosphate modifications, sugar modifications, and 2' modifications. Recent modifications include replacing the sugar with an alternative structure which has primary and a secondary alcohol groups similar to those of ribose. As used herein, these modified compounds are included within the definition of the term

5 "phosphorus-linked oligomer".

As used herein, the term "nucleoside phosphoramidite" is intended to denote a mono-, di- or polynucleotide species that has a phosphoramidite functionality attached, preferably at the 3'-terminal position, and which bears a 5'-hydroxyl protecting group.

Such phosphoramidite groups are known in the art to undergo a coupling reaction with the  
10 deprotected 5'-hydroxyl of a growing oligomeric chain according to standard synthetic methodologies. See for example Caruthers U.S. Patents Nos. 4,415,732; 4,458,066; 4,500,707; 4,668,777; 4,973,679; and 5,132,418; and Koster U.S. Patents Nos. 4,725,677 and Re. 34,069; and *Oligonucleotides and Analogues A Practical Approach*, Eckstein, F. Ed., IRL Press, New York, 1991, each of the disclosures of which are hereby incorporated  
15 by reference in their entirety. Thus, phosphoramidite groups include groups of formula -P(-O-Y)-N(I-pr)<sub>2</sub> where Y is a phosphoryl protecting group useful in phosphoramidite synthesis, such β-cyanoethyl and allyl (See Manoharan, M. et al., Org. Lett. (2000), 2(3), 243-246). Other such phosphoryl protecting groups include methyl, (N-methyl-N-benzoylamino)ethyl, (N-ethyl-N-benzoylamino)ethyl, 2-[N-methyl-N-(4-methoxybenzoyl)-  
20 amino]ethyl, 2-(N-isopropyl-N-benzoylamino)ethyl, 2-[N-ethyl-N-(4-methoxybenzoyl)-amino]ethyl, 2-[N-isopropyl-N-(4-methoxybenzoyl)amino]ethyl, 2-[N-methyl-N-(4-dimethylaminobenzoyl)amino]ethyl, 2-[N-isopropyl-N-(4-dimethylaminobenzoyl)amino]ethyl, 2-(thionobenzoylamino)ethyl, 3-[thionobenzoylamino]propyl, 2-(N-phenylthiocarbamoylamino)ethyl, 2-[(1-  
25 naphthyl)carbamoyloxy]ethyl, diphenylsilylethyl, δ-cyanobutenyl, cyano p-xylyl, methyl-N-trifluoroacetyl ethyl, and acetoxy phenoxy ethyl.

Typically, at the beginning of a solid phase phosphoramidite synthetic regime, a 5'-O-protected nucleoside synthon is first attached to a solid support through a linker. Solid supports are substrates which are capable of serving as the solid phase in  
30 solid phase synthetic methodologies, such as those described in Caruthers U.S. Patents Nos. 4,415,732; 4,458,066; 4,500,707; 4,668,777; 4,973,679; and 5,132,418; and Koster

U.S. Patents Nos. 4,725,677 and Re. 34,069. Linkers are known in the art as short molecules which serve to connect a solid support to functional groups (e.g., hydroxyl groups) of initial synthon molecules in solid phase synthetic techniques. One such linker is a succinamide linker. Other suitable linkers are disclosed in, for example,

- 5    5    *Oligonucleotides And Analogues A Practical Approach*, Ekstein, F. Ed., IRL Press, N.Y.,  
1991, Chapter 1, pages 1-23.

Solid supports according to the invention include those generally known in the art to be suitable for use in solid phase methodologies, including, for example, controlled pore glass (CPG), oxalyl-controlled pore glass (*see, e.g.*, Alul, *et al.*, *Nucleic*

- 10    10    *Acids Research* 1991, 19, 1527), TentaGel Support (an aminopolyethyleneglycol derivatized support (*see, e.g.*, Wright, *et al.*, *Tetrahedron Letters* 1993, 34, 3373)) and Poros (a copolymer of polystyrene/divinylbenzene). Those of skill in the art will appreciate that other solid support methodologies are equally amenable to the methods of the invention.

- 15    15    In accordance with some preferred embodiments of the methods of the invention, after the initial nucleoside synthon is attached to the solid support, and after each subsequent coupling cycle, the 5'-hydroxyl of the previously coupled monomeric or higher order synthon is deprotected with a deprotecting reagent, which can be any of a variety of reagents that are typically used for deprotection of 5'-hydroxyl groups in solid  
20    20    phase oligonucleotide synthesis. Typically, such deprotection reagents includes a protic acid in a solvent, which is typically a halogenated solvent such as dichloromethane or dichloroethane, and, optionally, an additive. Examples of such protic acids include formic acid, acetic acid, chloroacetic acid, dichloroacetic acid, trichloroacetic acid, trifluoroacetic acid, benzenesulfonic acid, toluenesulfonic acid, or phenylphosphoric acid.

- 25    25    In accordance with some preferred embodiments of the invention, the deprotected 5'-hydroxyl of the support bound nucleoside is then typically reacted with (i.e., coupled to) a 5'-protected activated phosphorus compound to produce a covalent linkage therebetween. Where the activated phosphorus compound is a phosphoramidite, a phosphite linkage is produced. Alternatively, other regimes known in the art can be  
30    30    employed to make other internucleoside linkages, for example H-phosphonate linkages and phosphoramidate linkages.

Typically, the 5'-protected phosphordiamidite to be coupled is activated to nucleophilic attack the 5' hydroxyl of the support bound oligomer by use of an activating agent. It is believed that the activating agent displaces one of the amino groups from the phosphordiamidite, thereby rendering the phosphorus of the phosphordiamidite more

5 susceptible to nucleophilic attack by the 5' hydroxyl group of the growing nucleotide chain. Any activating agent that can activate the phosphorous to nucleophilic attack without interacting with the growing nucleotide chain may be suitable for use with the present invention. One preferred activating agent is tetrazole. Some commonly used commercially available activating agents are thiotetrazole, nitrotetrazole, and N,N-

10 diisopropylaminohydrotetrazolide. Other suitable activating agents are also disclosed in the above incorporated patents as well as in United States patent 4,725,677 and in Berner, S., Muhlegger, K., and Seliger, H., *Nucleic Acids Research* 1989, 17:853; Dahl, B.H., Nielsen, J. and Dahl, O., *Nucleic Acids Research* 1987, 15:1729; and Nielson, J. Marugg, J.E., Van Boom, J.H., Honnens, J., Taagaard, M. and Dahl, O., *J. Chem. Research* 1986,

15 26, all of which are herein incorporated by reference.

In some applications of the phosphoramidite technique, each coupling step is followed by a sulfurization step or oxidation step to produce a phosphorothioate or phosphodiester linkage. Useful oxidizing agents according to the present invention include iodine, t-butyl hydroperoxide, or other oxidizing reagents known in the art.

20 Sulfurizing agents used during oxidation to form phosphorothioate linkages include Beaucage reagent (*see e.g.* Iyer, R.P., *et al.*, *J. Chem. Soc.*, 1990, 112, 1253-1254, and Iyer, R.P., *et al.*, *J. Org. Chem.*, 1990, 55, 4693-4699); tetraethylthiuram disulfide (*see e.g.*, Vu, H., Hirschbein, B.L., *Tetrahedron Lett.*, 1991, 32, 3005-3008); dibenzoyl tetrasulfide (*see e.g.*, Rao, M.V., *et al.*, *Tetrahedron Lett.*, 1992, 33, 4839-4842);

25 di(phenylacetyl)disulfide (*see e.g.*, Kamer, P.C.J., *Tetrahedron Lett.*, 1989, 30, 6757-6760); 1,2,4-dithiuazoline-5-one (DtsNH) and 3-ethoxy-1,2,4-dithiuazoline-5-one (EDITH) and (*see* Xu et al., *Nucleic Acids Research*, 1996, 24, 3643-3644 and Xu et al., *Nucleic Acids Research*, 1996, 24, 1602-1607); thiophosphorus compounds such as those disclosed in U.S. patent No. 5,292,875 to Stec et al., and U.S. patent No. 5,151,510 to Stec et al., disulfides of sulfonic acids, such as those disclosed in Efimov et al., *Nucleic Acids Research*, 1995, 23, 4029-4033, sulfur, sulfur in combination with ligands like triaryl,

trialkyl, triaralkyl, or trialkaryl phosphines.

The deprotection and coupling steps, and, optionally, oxidation or sulfurization steps, are repeated using mono-, di- or polymeric activated synthons until at least a portion of the desired base sequence is achieved.

5 In accordance with some preferred embodiments of the invention, the support bound oligomer will contain at least one phosphoryl internucleoside linkage that is not protected. Such an unprotected linkage or linkages can be formed by any of several methods, including, for example, by deprotection of protected phosphoryl groups on the support bound oligomer.

10 In accordance with some preferred embodiments of the invention, additional phosphoramidite synthesis according to the methods of the invention is performed on the support bound oligomer having at least one unprotected phosphoryl internucleoside linkage. In some preferred embodiments of the invention, the support bound oligomer is washed with a solution containing a neutralizing agent of the invention. This is followed  
15 by coupling of a monomeric or higher order nucleoside phosphoramidite. In other preferred embodiments of the invention, the aforementioned washing step is not performed, but rather the support bound oligomer is contacted with a solution that, in addition to the monomeric or higher order nucleoside phosphoramidite to be coupled, also contains has a neutralizing agent of the invention included therein.

20 In some preferred embodiments, the neutralizing agent of formula  $D^+ E^-$  is formed *in situ* from a 1H-tetrazole and an aliphatic amine, an aliphatic heterocyclic amine, an aromatic amine, an aromatic heterocyclic amine, or a guanidine, preferably in about equimolar amounts. While not wishing to be bound by a particular theory, it is believed that where the neutralizing agent is an amine, residual acidity present on the solid support  
25 aids in the formation of the protonated form of the amine.

In some preferred embodiments of the invention, concentration of neutralizing agent is from about 0.05M to about 0.15M, with from about 0.08M to about 0.12M being more preferred, with from about 0.09M to about 0.11M being more preferred, and with about 0.10M being especially preferred.

30 At the end of desired synthesis, the completed oligomer is cleaved from the solid support. Cleavage is achieved by any of the standard methods in the art, such as, for

example, with concentrated ammonium hydroxide. In some preferred embodiments, the conditions for cleavage from the solid support also removes protecting groups from internucleoside linkages, and from the constituent nucleobases.

The methods of the present invention can be used for the synthesis of


- 5 phosphorus-linked oligonucleotides having both naturally occurring and non-naturally occurring constituent groups. For example, the present invention can be used to synthesize phosphorus-linked oligomers having phosphodiester, phosphorothioate, phosphorodithioate, or H-phosphonate linkages, or having mixtures of such linkages, and which have naturally occurring pentose sugar components such as ribose and deoxyribose,
- 10 and their substituted derivatives, as well as other sugars known to substitute therefor in oligonucleotide analogs.

The constituent sugars and nucleosidic bases ("nucleobases") of the phosphorus-linked oligomers can be naturally occurring or non-naturally occurring. Non-naturally occurring sugars and nucleosidic bases are typically structurally distinguishable  
15 from, yet functionally interchangeable with, naturally occurring sugars (e.g. ribose and deoxyribose) and nucleosidic bases (e.g., adenine, guanine, cytosine, thymine). Thus, non-naturally occurring nucleobases and sugars include all such structures which mimic the structure and/or function of naturally occurring species, and which aid in the binding of the oligonucleotide to a target, or which otherwise advantageously contribute to the properties  
20 of the oligonucleotide.

The methods of the invention are amenable to the synthesis of phosphorus-linked oligomers having a variety of substituents attached to their 2'-positions. As used herein the term "sugar substituent group" or "2'-substituent group" includes groups attached to the 2' position of the ribosyl moiety with or without an intervening oxygen atom. 2'-Sugar modifications amenable to the present invention include fluoro, chloro, bromo, O-alkyl, O-alkylamino, O-alkylalkoxy, protected O-alkylamino, O-alkylamino-alkyl, O-alkyl imidazole, and polyethers of the formula (O-alkyl)<sub>m</sub>, where m is 1 to about 10. Preferred among these polyethers are linear and cyclic polyethylene glycols (PEGs), and PEG-containing groups, such as crown ethers, and other reported substituent groups.  
25  
30 See, Ouchi *et al.*, *Drug Design and Discovery* 1992, 9, 93; Ravasio *et al.*, *J. Org. Chem.* 1991, 56, 4329; and Delgado *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*

1992, 9, 249. Each of the foregoing references is hereby incorporated by reference in its entirety. Further sugar substituent groups are disclosed by Cook (*Anti-Cancer Drug Design*, 1991, 6, 585-607). Fluoro, O-alkyl, O-alkylamino, O-alkyl imidazole, O-alkylaminoalkyl, and alkyl amino substituents are described in United States Patent 5 Application serial number 08/398,901, filed March 6, 1995, entitled "Oligomeric Compounds having Pyrimidine Nucleotide(s) with 2' and 5' Substitutions," hereby incorporated by reference in its entirety.

Additional 2' sugar modifications amenable to the present invention include 2'-SR and 2'-NR<sub>2</sub> groups, where each R is, independently, hydrogen, a protecting group or 10 substituted or unsubstituted alkyl, alkenyl, or alkynyl. 2'-SR nucleosides are disclosed in United States Patent No. 5,670,633, issued September 23, 1997, hereby incorporated by reference in its entirety. The incorporation of 2'-SR monomer synthons are disclosed by Hamm *et al.*, *J. Org. Chem.*, 1997, 62, 3415-3420. 2'-NR<sub>2</sub> nucleosides are disclosed by Goettingen, M., *J. Org. Chem.*, 1996, 61, 6273-6281; and Polushin *et al.*, *Tetrahedron Lett.*, 1996, 37, 3227-3230. Further representative 2'-O-sugar modifications amenable to 15 the present invention include those having one of formula I or II:



wherein:

E is C<sub>1</sub>-C<sub>10</sub> alkyl, N(R<sub>12</sub>)(R<sub>13</sub>) or N=C(R<sub>12</sub>)(R<sub>13</sub>); 20 each R<sub>12</sub> and R<sub>13</sub> is, independently, H, C<sub>1</sub>-C<sub>10</sub> alkyl, a nitrogen protecting group, or R<sub>12</sub> and R<sub>13</sub>, together, are a nitrogen protecting group or are joined in a ring structure that includes at least one additional heteroatom selected from N and O; R<sub>14</sub> is OX<sub>1</sub>, SX<sub>1</sub>, or N(X<sub>1</sub>)<sub>2</sub>;

each  $X_1$  is, independently, H,  $C_1-C_8$  alkyl,  $C_1-C_8$  haloalkyl,  $C(=NH)N(H)Z_1$ ,  $C(=O)N(H)Z_1$  or  $OC(=O)N(H)Z_1$ ;

$Z_1$  is H or  $C_1-C_8$  alkyl;

$L_1$ ,  $L_2$  and  $L_3$  comprise a ring system having from about 4 to about 7 carbon atoms or having from about 3 to about 6 carbon atoms and 1 or 2 heteroatoms, said heteroatoms being selected from oxygen, nitrogen and sulfur, wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic;

$Y_m$  is  $C_1-C_{10}$  alkyl or haloalkyl,  $C_2-C_{10}$  alkenyl,  $C_2-C_{10}$  alkynyl,  $C_6-C_{14}$  aryl,  $N(R_{12})(R_{13})OR_{12}$ , halo,  $SR_{12}$  or  $CN$ ;

10 each  $q_1$  is, independently, an integer from 2 to 10;

each  $q_2$  is 0 or 1;

$p$  is an integer from 1 to 10; and

$q_3$  is an integer from 1 to 10;

provided that when  $p$  is 0,  $q_3$  is greater than 1.

15 In accordance with some preferred embodiments of the methods of the invention, oligomers can be prepared having regions which differ with respect to substituent bound to the 2'-position. Thus, in certain preferred embodiments, the methods of the invention are used to prepare so called "gapped" oligomers wherein, for example, the central portion of the oligomer contains a different 2'-substituent than the regions that form the 5' and 3' ends of the oligomer. Thus, it will be appreciated that the methods of the invention find applicability in the preparation of oligomers that have a plurality of such regions differing in 2'-substituent.

The methods of the invention also can be used to prepare oligomers having monomeric subunits that contain O-substitutions of the sugar (for example, ribose or deoxyribose) rings. Representative O-substitutions on the ribosyl ring include S,  $CH_2$ ,  $CHF$ , and  $CF_2$ , see, e.g., Secrist, *et al.*, *Abstract 21, Program & Abstracts, Tenth International Roundtable, Nucleosides, Nucleotides and their Biological Applications*, Park City, Utah, Sept. 16-20, 1992.


Representative nucleobases suitable for use in the methods of the invention 30 include adenine, guanine, cytosine, uridine, and thymine, as well as other non-naturally occurring and natural nucleobases such as xanthine, hypoxanthine, 2-aminoadenine, 6-

methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halo uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo uracil), 4-thiouracil, 8-halo, oxa, amino, thiol, thioalkyl, hydroxyl and other 8-substituted adenines and guanines, 5-trifluoromethyl and other 5-  
5 substituted uracils and cytosines, 7-methylguanine. Further naturally and non naturally occurring nucleobases include those disclosed in U.S. Patent No. 3,687,808 (Merigan, *et al.*), in chapter 15 by Sanghvi, in *Antisense Research and Application*, Ed. S. T. Crooke and B. Lebleu, CRC Press, 1993, in Englisch *et al.*, *Angewandte Chemie*, International Edition, 1991, 30, 613-722 (see especially pages 622 and 623, and in the *Concise*  
10 *Encyclopedia of Polymer Science and Engineering*, J.I. Kroschwitz Ed., John Wiley & Sons, 1990, pages 858-859, Cook, P.D., *Anti-Cancer Drug Design*, 1991, 6, 585-607. The terms "nucleosidic base" and "nucleobase" are further intended to include heterocyclic compounds that can serve as nucleosidic bases, including certain 'universal bases' that are not nucleosidic bases in the most classical sense, but function similarly to nucleosidic  
15 bases. One representative example of such a universal base is 3-nitropyrrole.

The methods of the present invention use labile protecting groups to protect various functional moieties during synthesis. Protecting groups are used ubiquitously in standard oligonucleotide synthetic regimes for protection of several different types of functionality. In general, protecting groups render chemical functionality inert to specific  
20 reaction conditions and can be appended to and removed from such functionality in a molecule without substantially damaging the remainder of the molecule. See, e.g., Green and Wuts, Protective Groups in Organic Synthesis, 2d edition, John Wiley & Sons, New York, 1991. Representative protecting groups useful to protect nucleotides during synthesis include base labile protecting groups and acid labile protecting groups. Base  
25 labile protecting groups are used to protect the exocyclic amino groups of the heterocyclic nucleobases. This type of protection is generally achieved by acylation. Two commonly used acylating groups for this purpose are benzoylchloride and isobutyrylchloride. These protecting groups are stable to the reaction conditions used during oligonucleotide synthesis and are cleaved at approximately equal rates during the base treatment at the end  
30 of synthesis.

Hydroxyl protecting groups typically used in oligonucleotide synthesis may

be represented by the following structure:



wherein each of R<sub>A</sub>, R<sub>B</sub> and R<sub>C</sub> is an unsubstituted or mono-substituted aryl or heteroaryl group selected from phenyl, naphthyl, anthracyl, and five or six membered heterocyclic

- 5 rings with a single heteroatom selected from N, O and S, or two N heteroatoms, including quinolyl, furyl, and thienyl; where the substituent is selected from halo (i.e., F, Cl, Br, and I), nitro, C<sub>1</sub>-C<sub>4</sub>-alkyl or alkoxy, and aryl, aralkyl and cycloalkyl containing up to 10 carbon atoms; and wherein R<sub>2</sub> and R<sub>3</sub> may each also be C<sub>1</sub>-C<sub>4</sub>-alkyl or aralkyl or cycloalkyl containing up to 10 carbon atoms.

10 In preferred embodiments of the invention, the 5'-protecting group is trityl, monomethoxy trityl, dimethoxytrityl, trimethoxytrityl, 2-chlorotriyl, DATE, TBTr, Pixyl or Moxyl, with trityl, monomethoxy trityl, dimethoxy trityl, 9-phenylxanthine-9-yl (Pixyl) or 9-(p-methoxyphenyl)xanthine-9-yl MOX) being more preferred, and with dimethoxy trityl being especially preferred.

15 Phosphorus linked oligomers produced by the methods of the invention will preferably be hybridizable to a specific target oligonucleotide. Preferably, the phosphorus linked oligomers produced by the methods of the invention comprise from about 1 to about 100 monomer subunits. It is more preferred that such compounds comprise from about 10 to about 30 monomer subunits, with 15 to 25 monomer subunits being 20 particularly preferred.

As will be recognized, the process steps of the present invention need not be performed any particular number of times or in any particular sequence. Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are not 25 intended to be limiting.

## EXAMPLES

### Materials and Methods

Anhydrous MeCN (water content <0.001%) was purchased from Burdick and Jackson (Muskegon, MI). Standard phosphoramidites **2** and **24–26**, thymidine *H*-phosphonate **27**, and ancillary reagents for oligonucleotide synthesis were purchased from Glen Research (Virginia). 2'-*O*-(2-Methoxyethyl) ribonucleoside phosphoramidites

- 5 **20–23** were obtained from Proligo Biochemie GmbH (Hamburg, Germany). All other reagents and dry solvents were purchased from Aldrich and used without further purification. Tentagel and controlled pore glass versions of the solid support **1** were synthesized as previously reported (See Pon, R. T. and Yu, S. *Nucleic Acids Res.* **1997**, *25*, 3629–3635).

10  $^{31}\text{P}$  NMR spectra in gel phase were recorded at 80.950 MHZ. The spectra were recorded using 10 to 15 mg of solid supports **3–8** loaded at 208  $\mu\text{mol g}^{-1}$  and  $\text{CD}_3\text{CN}$  as a liquid phase with the spinning switched off. With the phosphate-unprotected oligonucleotides **4–8**, the best resolution was obtained when an amine was added to the liquid phase (1M piperidine for **4** or 5% Py for **5–8**).

15 **HPLC Techniques.**

Crude **9a**, **11a**, **16a**, **18a**, and **32a** and **32b** were analyzed and isolated on a DeltaPak C18 column (15  $\mu\text{m}$ ; 300Å; 3.8  $\times$  300 mm) eluting with a linear gradient from 0 to 60% B in 40 min at a flow rate of 1.5 mL min<sup>-1</sup>. Oligonucleotides **9b**, **11b**, **16b**, and **18b** were analyzed using a linear gradient from 0 to 60% B in 30 min. 0.1M aq  $\text{NH}_4\text{OAc}$  and 20 80% aq MeCN were used as buffer A and buffer B, respectively.

**Oligonucleotide synthesis.**

The oligonucleotide synthesis was performed on an ABI 380B DNA Synthesizer. The phosphoramidite synthesis was carried out either according to the manufacturer's recommendations (Standard Cycle) or by a modified procedure.

- 25 Phosphoramidites **2** and **20–26** were used as 0.1M solutions in dry MeCN. For the attachment of phosphoramidites **20–23**, the coupling time was extended to 10 min. For preparation of the PS oligonucleotides, 3*H*-1,2-benzodithiol-3-one 1,1-dioxide (0.05M in MeCN) was used as a sulfur-transfer reagent (See Iyer, R. P.; Phillips, L. R.; Egan, W.;

Regan, J. B.; Beauchage, S. L. *J. Org. Chem.* **1990**, *55*, 4693–4699). For preparation of **16a** and **16b** and **18a** and **18b** by the modified cycle, the neutralizers, LiClO<sub>4</sub> or a tertiary amine (0.1M in MeCN) or mixtures containing 0.1M tertiary amine and 0.1M

*1H*-tetrazole, were prepared. These were placed in positions 15 or 17 of the synthesizer

- 5 (PS and PO cycles, respectively). The standard, 1 μmol protocol was modified in two respects. First, the delivery time for the capping reagents and the following wait time were extended to 45 sec each. This reduced dramatically the presence of the 5'-DMT-protected 19-mer and shorter oligonucleotides and thus simplified the calculation of yields for the less efficient syntheses. Secondly, the standard detritylation subroutine was followed by a  
10 brief washing with MeCN and flushing with argon. To convert the support-bound oligonucleotide to the required salt, the solution of a neutralizer was next delivered to the columns for 45 sec. Finally, the columns were washed with MeCN and flushed with argon prior to the coupling step, as in the standard protocol.

The *H*-phosphonate synthesis was carried out according to the manufacturers  
15 recommendations. Thymidine 3'-*H*-phosphonate **27** and the activator, pivaloyl chloride, were used as 0.05M solutions in MeCN–Py (50:50) and 0.2M solutions in MeCN–Py (95:5), respectively.


Solid support-bound **8**, **10**, **12**, and **17a** and **17b** were deprotected with concentrated aqueous ammonium hydroxide for 30 min at room temperature. Compounds  
20 **31a** and **31b** were deprotected for 6 h at 55 °C. The products, 5'-DMT protected crude oligonucleotides **9a** and **9b**, **11a** and **11b**, **16a** and **16b**, **18a** and **18b**, and **32a** and **32b**, were analyzed by reverse phase HPLC and characterized by electron-spray LCMS. The modified oligonucleotides **32a** and **32b** were isolated and desalted by reverse phase HPLC.

### Example 1

- 25 **Coupling of phosphoramidite 2 to unprotected hexathymidylates studied by <sup>31</sup>P NMR on solid support.**


While not wishing to be bound by any particular theory, it has been previously postulated that an activated phosphoramidite might react with an internucleosidic phosphate diester moiety to form a mixed anhydride, which could be

cleaved in the presence of excess  $1H$ -tetrazole to regenerate deoxyribonucleoside phosphorotetrazolide intermediates (See Caruthers, M. H. Kierzek, R., and Tang, J. Y., *supra*). Indirectly, this has been confirmed by the fact that the dimethoxytrityl responses measured after each elongation cycle were consistent with addition of only one equivalent of phosphoramidite. Because no similar information was available for phosphorothioate oligonucleotides, the reactivity of the solid support-bound oligonucleotides **4a** and **5a** with the phosphoramidite **2** was first studied.




**1a:** = Polystyrene


**1b:** = Controlled Pore Glass



**2**



**19** = Controlled Pore Glass



**20-26**

Base	R
<b>20</b> Ade <sup>bz</sup>	$\text{OCH}_2\text{CH}_2\text{OMe}$
<b>21</b> Cyt <sup>bz</sup>	$\text{OCH}_2\text{CH}_2\text{OMe}$


<b>22</b> Gua <sup>ibu</sup>	$\text{OCH}_2\text{CH}_2\text{OMe}$
------------------------------	-------------------------------------

<b>23</b> Thy	$\text{OCH}_2\text{CH}_2\text{OMe}$
---------------	-------------------------------------


<b>24</b> Ade <sup>bz</sup>	H
-----------------------------	---

<b>25</b> Cyt <sup>ac</sup>	H
-----------------------------	---

<b>26</b> Gua <sup>ibu</sup>	H
------------------------------	---



**27**



(a) 1M piperidine/MeCN; (b)  $\text{Cl}_2\text{HCCO}_2\text{H}$  (3% in  $\text{CH}_2\text{Cl}_2$ ); (c)  $3\text{H}-1,2\text{-benzodithiol-3-one 1,1-dioxide}/\text{MeCN}$ . **3a–9a:** X = S;  
**3b–9b:** X = O.

5

**Scheme 1**

In order to obtain **4a**, its 2-cyanoethyl protected precursor **3a** was synthesized on a 40  $\mu\text{mol}$  scale on a high-loaded polystyrene support **1a** (See Pon et al.,

*supra)* using phosphoramidite chemistry (Scheme 1).

The solid support-bound **3a** was treated with 1M piperidine in anhydrous MeCN. The progress of the deprotection was monitored by  $^{31}\text{P}$  NMR in gel phase. After 1.5 h at room temperature, the peak at 67.8 ppm was replaced by a peak at 57.3 ppm, which reflected the conversion of the thionophosphate triester **3a** to the corresponding diester **4a** in more than 98% yield. At the same time, the diglycolyl linker (See Pon et al., *supra*) that anchored the oligonucleotide to the solid support was not cleaved to any appreciable extent. On completion of deprotection, **4a** was washed with excess MeCN and detritylated to give **5a**.

The solid supports **4a** and **5a** were treated with **2** (0.1M in MeCN) in the presence of *1H*-tetrazole for 10 min on a DNA synthesizer followed by excessive washing with MeCN. The  $^{31}\text{P}$  NMR spectrum of the product obtained from **4a** revealed only the peak of the starting material. For **5a**, two peaks at 140.6 and 57.5 ppm in a ratio of 1:5.06 were observed, which agreed with the formation of **6a** in *ca.* 99% yield. When sulfurized with *3H*-1,2-benzodithiol-3-one 1,1-dioxide (See Iyer et al., *supra*), **6a** gave **7a** (peaks at 67.9 and 57.5 ppm) in quantitative yield.

In a similar manner, **4a** and **5a** were treated with the standard capping mixture ( $\text{Ac}_2\text{O}/N$ -methylimidazole/pyridine/THF) for 30 min in a NMR tube. No apparent changes in the  $^{31}\text{P}$  NMR spectra of both compounds were observed.

When four additional coupling cycles were carried out with **7a**, solid support-bound **8a** was obtained. In the  $^{31}\text{P}$  NMR spectrum of **8a**, the peaks of the protected and the deprotected PS moieties were displayed at 67.8 and 56.8 ppm, respectively, in a 50:50 ratio. Additionally, a minor peak of desulfurized phosphates was observed at -1.5 ppm and accounted for *ca.* 2% of the total integration area.

Analogous observations were made when oligonucleotides **3b**–**8b** were synthesized. These experiments confirmed that no stable products are formed between phosphodiester groups and the nucleoside phosphoramidite **2** or  $\text{Ac}_2\text{O}$  in the presence of *1H*-tetrazole and *N*-methylimidazole, respectively. They also demonstrated that the hypothesis holds true for thionophosphate diesters.


The solid support-bound compounds **8a** and **8b** were treated with

concentrated aqueous ammonium hydroxide to give **9a** and **9b**, respectively. The reverse phase HPLC analysis of the crude products suggested an average coupling efficiency that did not exceed 94–95%. In addition, during the synthesis of **8a** and **8b** we observed some detritylation during the coupling step.

- 5 While not wishing to be bound by any particular theory, possible explanations for the low coupling efficiency may be posited using compounds **13–15** in Scheme 2 as illustrations. After the phosphate-unprotected oligonucleotide **13** is detritylated on a DNA synthesizer by treatment with dichloroacetic acid ( $pK_a$  1.30 in water; See Gould, E. S. *Mechanism and Structure in Organic Chemistry*; Henry Holt and Company: New York, 1960, p. 201), the phosphodiester backbone may be at least partially converted to an acid **14** (Scheme 2). After washing with MeCN, **14** is treated with a phosphoramidite building block and  $1H$ -tetrazole. In the standard protocols for DNA synthesis, phosphoramidite building blocks are used, depending on the synthetic scale, in a two to tenfold excess over the 5'-hydroxy groups of the support-bound oligonucleotide.
- 10 Thus, for the 11-mer oligonucleotide **14**, the concentration of the support-bound dinucleoside phosphoric acid in the reaction volume may exceed or at least be comparable to the concentration of the phosphoramidite. This may lead to the unwanted partial detritylation and inactivation of the monomer and result in lower coupling yields. Thus, in accordance with the present invention, prior to the coupling step, **14** was neutralized, *i.e.*,
- 15 converted to a salt **15** using a base or a salt of the base. Preferably, the counterion,  $BH^+$  or  $M^+$ , should be inert towards nucleoside phosphoramidites.
- 20

### Example 2

**Coupling of phosphoramidite 2 to oligonucleotides with neutralized phosphodiester groups.**



(a) 1M piperidine/MeCN; (b) DNA synthesis using, after detritylation, additional wash with 0.1M Base/MeCN, 0.1M Base + 0.1M 1*H*-tetrazole, or 0.1M LiClO<sub>4</sub>/MeCN; (c) Cl<sub>2</sub>HCCO<sub>2</sub>H (3% in CH<sub>2</sub>Cl<sub>2</sub>); (d) 0.1M Base/MeCN, 0.1M Base + 0.1M 1*H*-tetrazole, or 0.1M LiClO<sub>4</sub>/MeCN. **10a–18a:** X = S; **10b–18b:** X = O.

**Scheme 2**

In order to study the effect of the counterion on the efficiency of the phosphoramidite coupling, model experiments were carried out as presented in Scheme 2.

Starting from **1b**, protected 3'-segments **10a** and **10b** were first synthesized on a 30 μmol scale in a standard manner. Small aliquots of **10a** and **10b** (0.5 μmol) were 5 conventionally deprotected to give **11a** and **11b**, which were characterized by ESMS and HPLC. Approximately one half of **10a** and **10b** was converted to the unprotected 3'-segments **13a** and **13b** as described for compound **8a**. With these as starting material, further chain elongation was carried out on a 1 μmol scale until protected 9-mer 5'-segments were assembled to give **17a** and **17b** and **18a** and **18b**. For comparison, 10 control samples of the same sequence, **12a** and **12b** and **16a** and **16b**, were synthesized from **10a** and **10b** on a parallel column using the identical scale, protocols and conditions. In comparison with the experimental design for compound **8**, this offered two distinct advantages. First, a longer 11-mer 3'-segment allowed one to observe a more pronounced negative effect of the unprotected phosphate backbone. Secondly, at a high coupling 15 efficiency, assembling a protected 9-mer 5'-segment resulted in greater differences in yields between the experimental and the control samples, **16** and **18**, respectively. This led to a more accurate determination of the stepwise yields for the 5'-segment of **16** and **18** and more reliable results regarding the coupling efficiency.

The standard protocol for the DNA synthesis on a 1 μmol scale was modified 20 in two aspects. First, delivery and wait times on the capping step were each extended to 45 sec. This reduced dramatically the abundance of DMT-positive (n-1)-mer and shorter oligonucleotides and thus simplified the calculation of yields for the full-length oligonucleotides. Secondly, the standard detritylation subroutine was followed by a modified washing protocol. To convert the detritylated, support-bound oligonucleotides to 25 the required salt, a solution of a neutralizer, *i.e.*, an organic base or a salt was delivered to the columns for 45 sec. Then, in accordance with the standard protocol, the columns were washed with MeCN, and the coupling subroutine was carried out.

For neutralization of the phosphorothioate and phosphodiester (PS and PO, respectively) backbones, a number of amines, *i.e.*, pyridine (Py), 2,6-lutidine (Lut), 30 2,4,6-collidine (Col), *N*-methylmorpholine (NMM), *N,N*-diisopropylethylamine

(DIPEA), and triethylamine (TEA) were used as 0.1M solutions in MeCN. The  $pK_{BH^+}$  (MeCN) values of the conjugated acids of these amines covered a wide range from 12 to 18.5, so that a possible dependence of the acidity of a protonated amine on the coupling efficiency could be revealed (for  $pK_{BH^+}$  values in MeCN, see: (a) Py, 12.33; Lut, 13.92; 5 Col, 14.77; DMAP, 17.74; DBU, 24.13 (Kaljurand, I.; Bodima, T.; Leito, I.; Koppel, I. A.; Schwesinger, R. *J. Org. Chem.* **2000**, *65*, 6202–6208); (b) NMM 15.59 (Izutsu, K. *Acid-Base Dissociation Constants in Dipolar Aprotic Solvents*; Blackwell Scientific Publ.: Oxford, 1990; 166 pp.); (c) DIPEA 18.00 (estimated; the experimental value for DIPEA does not appear to have been reported); (d) TEA, 18.46 (Coetzee, J.F.; Padmanabhan, G.R. 10 *J. Am. Chem. Soc.* **1965**, *87*, 5005–5010); (e) TMG, 23.3 (Schwesinger, R. *Nachr. Chem., Tech. Lab.* **1990**, *38*, 1214–26)).

On completion of the synthesis, **12a** and **12b** and **17a** and **17b** were treated with concentrated ammonium hydroxide for 30 min to give crude **16a** and **16b** and **18a** and **18b**, respectively. These were analyzed by reverse phase HPLC. Average stepwise 15 coupling yields and total yields for the 5'-segments of the full-length oligonucleotides **16a** and **16b** and **18a** and **18b** were next calculated. The data obtained are presented in Fig. 1 (**16a** and **18a**) and 3 (**16b** and **18b**). The total yields of the 5'-segments of the oligonucleotides are plotted against the  $pK_{BH^+}$  (MeCN) values of the protonated bases that served as counterions for the PS or PO residues. Horizontal grids in Fig. 1–3 represent the 20 yields **18a** and **18b** obtained using the standard cycle.

As seen from Figs. 1 and 3, the yields of **16a** and **16b** were not influenced by the nature of the neutralizer except when DIPEA and TEA free bases were used for the preparation of **16a** (Fig. 1). In agreement with the preliminary results for **9a** and **9b**, the preparation of **18a** and **18b** using the standard cycle resulted in significantly lower yields 25 of the products. The stepwise yield of **18b** (96.4%) correlated perfectly with the reported value of 96% (See Caruthers, M.H., Kierzek, and Tang, J.T., *supra*). In contrast, when tertiary amines were used as neutralizers, improved yields of **18a** and **18b** were obtained. This effect depended on the  $pK_{BH^+}$  value of the counterion. As seen in Fig. 1, for the free amines, the yields of **18a** reached their maximum around  $pK_{BH^+}$  value of protonated 30 NMM. With more basic amines, DIPEA and TEA, lower yields of both **16a** and **18a** were

obtained. While not wishing to be bound by any particular theory, it is possible that amines as strong as DIPEA and TEA might cause a partial decyanoethylation in the course of the neutralization step, which generated additional unprotected phosphates and thus decreased the efficiency of the synthesis for both **16a** and **18a**.

To confirm that the use of a free base was not mandatory for an efficient cation exchange between the solid support-bound PS or PO moieties and the solution of a neutralizing agent, solutions of DBU (See Kaljurand et al., *supra*) in MeCN were mixed with different concentrations of *1H*-tetrazole (Tet) or with AcOH. As an example of inorganic salts, LiClO<sub>4</sub>, which is readily soluble in MeCN, was tested. These agents were used as neutralizers in the synthesis of **16a** and **18a** as described above for the free amines. The highest yields of **16a** and **18a** were obtained with a mixture of 0.1M DBU and 0.1M Tet (93.3 and 75.4%, respectively). Very similar results were obtained for both oligonucleotides when a slight excess (0.11 M) of Tet was present. In contrast, the yields of **16a** and **18a** were dramatically lower (by 29 and 11%, respectively) when excess DBU was used (0.10 M DBU + 0.09 M Tet). Similarly, using an equimolecular mixture of DBU and glacial AcOH or a solution of LiClO<sub>4</sub> reduced the yield of **16a** by more than 20%.

A number of strong amines, *i.e.*, NMM, 4-dimethylaminopyridine (DMAP) (See Kaljurand et al., *supra*), DIPEA, TEA, and *N,N,N',N'*-tetramethylguanidine (TMG) (See schwesinger et al., *supra*) were tested as equimolecular mixtures with Tet. At 0.1M concentration, all salts with Tet were readily soluble in dry MeCN and thus could be used safely on a DNA synthesizer. As seen in Figs. 2 and 3, the use of these agents had no adverse effect on the synthesis of **16a** and **16b**. Moreover, the yields of **18a** and **18b** obtained with *1H*-tetrazolides of NMM, DIPEA, and TEA were higher than with the corresponding free amines.

With neutralizing agents other than the mixture of DMAP and Tet, the yields of **18a** and **18b** reached a plateau around the pK<sub>BH+</sub> value of protonated DIPEA and then remained independent of the acidity of the protonated amine.

The pattern of the experimental curves was characteristic for the titration, which is most apparent for **18b** (Fig 3). In addition, the datapoints in Fig. 3 were best fitted using the Henderson-Hasselbach equation (See, for example: Atkins, P. W. *Physical*

*Chemistry*, 3rd Ed.; W. H. Freeman and Co.: New York, 1985, p. 280) which, in the present case, was transformed to eq (1):

$$pK_{BH^+} = (14.83 \pm 0.05) + \lg \left( \frac{Y - Y_{\min}}{Y_{\max} - Y} \right); \quad (1)$$

$$\text{where } \frac{Y - Y_{\min}}{Y_{\max} - Y} = \frac{[A^-]}{[HA]}$$

While not wishing to be bound by any particular theory, it would be expected  
 5 that, at low  $pK_{BH^+}$  of a neutralizing base, the internucleosidic moiety may present itself as the  $O,O'$ -dinucleoside phosphoric acid (HA). At high  $pK_{BH^+}$ , it is mostly ionized to form the corresponding phosphate anion ( $A^-$ ). It can be seen from Fig. 3 that both HA and  $A^-$  display a negative effect on the yield of **18b** ( $Y$ , %). However, the effect of  $A^-$  is less pronounced, which is reflected in a higher yield of **18b** ( $Y_{\max} = 85.1\%$ ) at high  $pK_{BH^+}$ . In  
 10 contrast, the species HA that are dominant at low  $pK_{BH^+}$  reduce the yield of **18b** more substantially ( $Y_{\min} = 75.4\%$ ).

It has been reported recently that tertiary ammonium azolide salts provide a more efficient catalysis in alcoholysis of dialkyl tetrazolylphosphonite than the corresponding azoles or tertiary amines (See Nurminen, E. J.; Mattinen, J. K.; Lönnberg,  
 15 *H. J. Chem. Soc. Perkin Trans. 2* 1999, 2551–2556). The catalytic effect of the salts correlated with the difference in the pK values of the acid and the base components, with the salts of stronger protolytes being more powerful catalysts. Therefore, while not wishing to be bound by a particular theory, it is also possible that the observed improvement in the yields of **18a** and **18b** arises, at least partially, from the catalytic effect of tertiary  
 20 ammonium salts on the phosphoramidite coupling.

The yields of **18a** and **18b** that were obtained using DMAP-Tet departed from the general trend and were markedly higher than might be expected from the  $pK_{BH^+}$  value of the protonated DMAP (Fig. 2 and 3). The mean total yields of the 5'-segments of **18a** and **18b** were  $86.4 \pm 0.2\%$  and  $92.2 \pm 0.3\%$  ( $n = 4$ ), or only 4 and 3% lower than the  
 25 yields of **16a** and **16b**, respectively. These data corresponded to the average stepwise yield

of 98.4 and 99.1% for the PS and PO coupling cycles.

While not wishing to be bound by any particular theory, one can explain the effect of the DMAP 1*H*-tetrazolide by one considering the outstanding catalytic ability of DMAP in nucleophilic reactions. It is believed that an activated phosphoramidite may 5 form a mixed anhydride with an internucleosidic phosphate diester group. In the presence of excess 1*H*-tetrazole, this intermediate could be cleaved to regenerate the activated phosphoramidite, nucleoside phosphorotetrazolide (See (a) Caruthers, M.H., Kierzek, and Tang, J.T.; and (b) Bruzik et al., *supra*). As seen from the results of the  $^{31}\text{P}$  NMR studies, the mixed anhydride is a short-lived intermediate that is not observed directly. However, 10 by forming the mixed anhydride, the internucleosidic phosphates may efficiently compete with the 5'-hydroxy groups for the reactive species. Accordingly, the positive effect of DMAP may consist in catalyzing the reverse reaction, i.e., the regeneration of the nucleoside phosphorotetrazolide. Alternatively, DMAP may catalyze the coupling to the 5'-hydroxy groups in a similar manner to the reported observations concerning the 15 synthesis of oligoribonucleotides (See Pon, R. T. *Tetrahedron Lett.* **1987**, *28*, 3643–3646).


The results presented herein show that the efficiency of the phosphoramidite coupling to phosphate unprotected oligonucleotides is lower than with the standard, protected oligonucleotides. However, the efficiency of the synthesis can be improved by compounds of the invention, particularly 0.1M DMAP 1*H*-tetrazolide in MeCN, for the 20 neutralization of the PS or PO backbone. Under optimized conditions, stepwise yields as high as 98+% were obtained.

### Example 3

#### Synthesis of modified oligonucleotides using phosphoramidite and H-phosphonate methods in succession.

25 The practical utility of phosphoramidite coupling to phosphate-unprotected oligonucleotides was demonstrated by preparing chimeric antisense oligonucleotides **32a** and **32b** against human MDM2 mRNA. As depicted in Scheme 3, compounds **32a** and **32b** comprised three segments consisting of PS and nucleoside-3'-phosphoramidate (PN) linkages. In addition, six 2'-*O*-(2-methoxyethyl) ribonucleoside (MOE) residues (see

Martin, P. *Helv. Chim. Acta* 1995, 78, 486-504) were introduced at each terminus of **32a** and **32b**.



- (a) Phosphoramidite synthesis using **20** and **22-26**; (b) *H*-phosphonate synthesis using **27** and pivaloyl chloride as an activator; (c) I:  $\text{RNH}_2$  (5% in  $\text{CCl}_4$ ), 3 h/RT; ii:  $\text{Ac}_2\text{O}/\text{N-methylimidazole/Py/THF}$ , 2 h/RT; (d) phosphoramidite synthesis using **20-23** and washing with 0.1M DMAP + 0.1M 1*H*-tetrazole in MeCN after detritylation. 2'-*O*-(2-Methoxyethyl)

ribonucleoside residues are shown in bold italicized letters.

### Scheme 3

Starting from **19**, a solid support-bound, protected oligonucleotide **28**, whose thionophosphate triester internucleosidic linkages (PPS) were protected with 2-cyanoethyl groups, was first synthesized by the phosphoramidite method using the commercially available building blocks **20** and **22–26**. The synthesis then proceeded with assembly of the segment 2 by the *H*-phosphonate method using **27** as a building block and pivaloyl chloride as the activator. The product **29** was converted to **30a** and **30b** by oxidative amidation of *H*-phosphonate linkages with a solution of a primary amine in  $\text{CCl}_4$  as described previously (See Maier, M. A.; Guzaev, A. P.; Manoharan, M. *Org. Lett.* **1999**, *2*, 1819–1822). Simultaneously, the 2-cyanoethyl protecting groups were removed to convert the PPS groups in segment 1 to the deprotected thionophosphate diester internucleosidic linkages, PS. In addition, treatment with primary amines partially removed, the base protecting groups. These were restored by acylation with the standard capping reagent ( $\text{Ac}_2\text{O}/\text{N}$ -methylimidazole/Py/THF) for 2 h.

It has been previously reported that the chain elongation by the *H*-phosphonate approach can be carried out efficiently with solid support-bound, phosphate unprotected oligonucleotides (See Gryaznov, S. M.; Potapov, V. K. *Tetrahedron Lett.* **1991**, *32*, 3715–3718). Therefore, the synthesis of the oligonucleotide analogs of **32a** and **32b** could be completed using the *H*-phosphonate building blocks. However, the *H*-phosphonate counterparts of the building blocks **20–23** are not available commercially and hence they have to be synthesized, purified, and characterized as described previously.<sup>13</sup> Similarly, many other nucleosidic and non-nucleosidic building blocks for the preparation of modified oligonucleotides are less commonly used and are commercially available only as 2-cyanoethyl phosphoramidites.

Using the methods of the present invention, one can avoid the synthesis of unusual *H*-phosphonate building blocks. Starting from **30a** and **30b**, the synthesis was resumed by the phosphoramidite method with **20–23** as building blocks. The synthesis was carried out using the modified elongation cycle where detritylation was followed by

washing with the neutralizer (0.1M DMAP and 0.1M Tet) as described above for **18a** and **18b**. The products **31a** and **31b** were deprotected with concentrated ammonium hydroxide in a conventional manner to give **32a** and **32b**. These were isolated by reverse phase HPLC in 33% and 36% yield, respectively, and characterized by ESMS. By comparison, when the 5 standard cycle was used, the yield of **32a** was only 12%.

### Calculations.

The accurate calculation of the stepwise yields in oligonucleotide synthesis requires the use of a complex mathematical model. See (a) Foldes-Papp, Z.; Baumann, G.; Birch-Hirschfeld, E.; Eickhoff, H.; Greulich, K. O.; Kleinschmidt, A. K.; Seliger, H. 10 *Biopolymers* **1998**, *45*, 361–379; (b) Foeldes-Papp, Z.; Birch-Hirschfeld, E.; Eickhoff, H.; Baumann, G.; Peng, W. G.; Biber, Thomas; Seydel, R.; Kleinschmidt, A. K.; Seliger, H. *J. Chromatogr., A* **1996**, *739*, 431–447; (c) Foeldes-Papp, Z.; Peng, W. G.; Seliger, H.; Kleinschmidt, A. K. *J. Theor. Biol.* **1995**, *174*, 391–408. Herein, a simpler (and less accurate) approach was used. For calculations of stepwise yields for normal and phosphate-15 deprotected oligonucleotides, it was assumed that the unreacted 5'-hydroxy functions were acetylated quantitatively on the capping step. Since, even with an extended capping protocol, this condition is not completely met, the calculated values are somewhat higher than the actual yields. Apparently, the lower the coupling efficiency is, the more abundant the uncapped DMT-positive shortmers are. Thus, the calculated values are less accurate 20 when the coupling yields are low. In contrast, for highly efficient syntheses, the calculated results are very accurate.

The homobasic oligonucleotides were assembled on a nucleosidic solid support in two segments, *n* and *m* phosphate residues in length, in the average stepwise coupling yields *x* and *y* for the 3'- and 5'-segments, respectively. On completing the 25 synthesis of the 3'-segment, an aliquot of solid support-bound oligonucleotide was withdrawn, deprotected with aqueous ammonium hydroxide, and analyzed by HPLC. From the HPLC-trace, the ratio of the integrated areas for full-length, DMT-On product and DMT-Off shortmers,  $R_{(3'-sgm)}$  was determined. The equation (S1) was solved numerically for *x*:

$$R_{(3'-sgm)} - \frac{(n+1)x^n}{(1-x)\sum_{n=1}^n nx^{n-1}} = 0 \quad (S1)$$

- On completing the synthesis of the 5'-segment, the solid support-bound oligonucleotide was treated as described above. In a similar manner, the ratio of the integrated areas for the full-length, DMT-On product and the DMT-Off shortmers,  $R_{(5'-sgm)}$  was determined. The 5 equation (S2) where  $x$  is known from solving the equation (S1) above was solved numerically for  $y$ :

$$R_{(5'-sgm)} - \frac{(m+n+1)x^n y^m}{(1-x)\sum_{n=1}^n nx^{n-1} + (1-y)x^n \sum_{m=1}^m (n+m)y^{m-1}} = 0 \quad (S2)$$

The total yield of the 5'-segment was found as ( $y^m \cdot 100\%$ ). The calculated values for the total yield and the average stepwise yield ( $y \cdot 100\%$ ) are presented in Table 1.

10 **Table S1. Calculated Average Stepwise and Total Yields for the 5'-Segments of  
Oligonucleotides 16a and 16b and 18a and 18b.**

Washing Protocol	Yield, % <sup>a</sup>							
	16a, per step	16a, total	18a, per step	18a, total	16b, per step	16b, total	18b, per step	18b, total
Standard cycle	99,17	92,79	93,78	56,08	99,43	95,00	96,33	71,42
0.1 M Py	98,96	91,02	92,94	51,74	99,58	96,25	96,92	75,44
0.1 M Lut	99,08	92,02	95,35	65,13	99,38	94,54	97,05	76,38
0.1 M Col	99,05	91,76	95,79	67,90	99,38	94,59	97,54	79,93
0.1 M NMM	98,92	90,69	96,15	70,23	—	—	—	—
0.1 M DIPEA	98,63	88,36	95,30	64,85	—	—	—	—
0.1 M TEA	98,67	88,67	95,15	63,93	—	—	—	—
0.1 M NMM; 0.1 M 1 <i>H</i> -tetrazole	99,03	91,60	96,42	72,00	99,50	95,55	98,03	83,57

	0.1 M DMAP; 0.1 M 1 <i>H</i> -tetrazole <sup>b</sup>	98,883± 0,023	90,385 ±0,186	98,393± 0,023	86,43 6±0,1 79	99,403± 0,011	94,75 6±0,2 97	99,107± 0,013	92,24 5±0,3 39
5	0.1 M DIPEA; 0.1 M 1 <i>H</i> -tetrazole	99,01	91,44	96,80	74,61	99,42	94,94	98,18	84,76
10	0.1 M TEA; 0.1 M 1 <i>H</i> -tetrazole	99,04	91,68	96,53	72,77	99,62	96,66	98,22	85,06
15	0.1 M DBU; 0.1 M 1 <i>H</i> -tetrazole	99,23	93,28	96,91	75,39	99,59	96,36	98,27	85,50
20	0.1 M DBU; 0.09 M 1 <i>H</i> -tetrazole	95,23	64,41	95,58	66,59	—	—	—	—
25	0.1 M DBU; 0.11 M 1 <i>H</i> -tetrazole	99,12	92,36	96,75	74,30	—	—	—	—
	0.1 M DBU; 0.1 M AcOH	95,96	68,99	96,26	70,95	—	—	—	—
	0.1 M TMG; 0.1 M 1 <i>H</i> -tetrazole	99,08	92,05	96,60	73,23	99,35	94,34	98,22	85,06
	0.1 M LiClO <sub>4</sub>	93,81	57,24	92,62	50,18	89,18	35,69	85,87	25,38

a. Mean values were calculated from the results of two independent experiments.

b. Mean values and standard errors were calculated from the results of four independent experiments.

Table S2. ESMS Data for oligonucleotides 11a and 11b, 16a and 16b, 18a and 18b,

30 and 32a and 32b.<sup>a</sup>

Compound	Sequence (5' → 3')	Observed Mass	Expected Mass
<b>11a</b>	DMT-(TpS) <sub>10</sub> T	3746.73	3747.20
<b>16a</b> , Standard cycle	DMT-(TpS) <sub>19</sub> T	6629.25	6629.54
<b>16a</b> , using DMAP-Tet	DMT-(TpS) <sub>19</sub> T	6629.09	6629.54
<b>18a</b> , using DMAP-Tet	DMT-(TpS) <sub>19</sub> T	6629.19	6629.54
<b>11b</b>	DMT-(TpO) <sub>10</sub> T	3586.22	3586.53
<b>16b</b> Standard cycle	DMT-(TpO) <sub>19</sub> T	6323.88	6324.27
<b>16b</b> , using DMAP-Tet	DMT-(TpO) <sub>19</sub> T	6424.10	6324.27

<b>18b</b> , using DMAP-Tet	DMT-(TpO) <sub>19</sub> T	6323.91	6324.27
<b>32a<sup>b</sup></b>	DMT-agct <sub>2</sub> c (TpN <sup>1</sup> ) <sub>3</sub> GCACA tgta <sub>3</sub>	7776.4	7774.8
<b>32b<sup>b</sup></b>	DMT-agct <sub>2</sub> c (TpN <sup>2</sup> ) <sub>3</sub> GCACA tgta <sub>3</sub>	7819.5	7816.9

- a. 2'-deoxy and 2'-O-(2-methoxyethyl)nucleosides are given in upper and lower case, respectively;  
5 pS, pO, pN<sup>1</sup>, and pN<sup>2</sup> stand for phosphorothioate, phosphate, N-(N,N-dimethylaminoethyl) phosphoramidate, and N-(N,N-dimethylaminopropyl) phosphoramidate internucleosidic linkages.  
b. Unless it is specified otherwise, the backbone is phosphorothioate

It is intended that each of the patents, applications, printed publications, and other published documents mentioned or referred to in this specification be herein  
10 incorporated by reference in their entirety.

Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true  
15 spirit and scope of the invention.